Login to Your Account

ChronTech's Stock Plummets on HCV Vaccine Phase II Miss

By Cormac Sheridan
Staff Writer

Wednesday, April 3, 2013

Shares in ChronTech Pharma AB plunged as much as 40 percent during trading Tuesday on news that ChronVac-C, the company's therapeutic DNA vaccine for treating hepatitis C virus (HCV) infection, failed to attain efficacy in an interim analysis of data from a Phase II trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription